ARQT Forecast


Bullish Case: With recent positive 56-week data and potential FDA approval of roflumilast, ARQT could experience substantial upside. Historical returns suggest rare but significant positive returns.


Bearish Case: Potential risks include stock dilution and market saturation. The recent flat price action reflects investor caution, and high implied volatility indicates market uncertainty.


Potential Outcomes:

1. FDA Approval of Roflumilast (45%): +50% increase.

2. Significant Stock Dilution (35%): -30%.

3. Market Saturation and Flat Trading (20%): Neutral price impact. Predictions based on data trends and industry analyst reports.


Trading Oracle: Sign Up to access trading oracle trade ideas.


July 21, 2024


Arcutis Biotherapeutics Forecast

ARQT      Arcutis Biotherapeutics











Correlated Assets

Assets that tend to move strongly with ARQT



XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.61)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (0.6)


LI Forecast + Options Trading Strategies   LI  Li Auto (-0.21)


VFC Forecast + Options Trading Strategies   VFC  VF (-0.37)



Uncorrelated Assets

Assets with little price relationship to ARQT



LI Forecast + Options Trading Strategies   LI  Li Auto (-0.21)


VFC Forecast + Options Trading Strategies   VFC  VF (-0.37)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (0.6)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.61)



Anticorrelated Assets

Assets that tend to move strongly against ARQT



XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (0.61)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (0.6)


LI Forecast + Options Trading Strategies   LI  Li Auto (-0.21)


VFC Forecast + Options Trading Strategies   VFC  VF (-0.37)





Become a more profitable investor with AI optimized trading strategies






×

Chat with ARQT


 Ask any question about ARQT!